It is well known that intratumoral and plasma levels of the phosphoprotein OPN are increased in many tumors such as lung cancer [21], esophageal cancer [22], prostate cancer [23], glioma [24], soft tissue sarcoma [25] and breast cancer [5,14]. Here, SPP1 is linked to prostate carcinoma.